Novartis announced that its investigational therapy, ianalumab, has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for Sjögren’s disease. The Breakthrough Therapy designation is intended to help speed the development and review of treatments for serious conditions with significant unmet needs. This designation is supported by positive results from multiple studies, including phase III trials.
While ianalumab is not yet approved, this update reflects continued progress in Sjögren’s research. The Sjögren's Foundation is encouraged to see growing attention and investment in multiple potential therapies, which brings hope for more options for patients in the future.
Read the full Novartis announcement.
Novartis announced that its investigational therapy, ianalumab, has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for Sjögren’s disease. The Breakthrough Therapy designation is intended to help speed the development and review of treatments for serious conditions with significant unmet needs. This designation is supported by positive results from multiple studies, including phase III trials.
While ianalumab is not yet approved, this update reflects continued progress in Sjögren’s research. The Sjögren's Foundation is encouraged to see growing attention and investment in multiple potential therapies, which brings hope for more options for patients in the future.
Read the full Novartis announcement.